Literature DB >> 28445850

Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning.

Arjen M Punt1, Jurgen B Langenhorst2, Annelies C Egas2, Jaap Jan Boelens2, Charlotte van Kesteren2, Erik M van Maarseveen2.   

Abstract

In allogeneic hematopoietic cell transplantation (HCT) it has been shown that over- or underexposure to conditioning agents have an impact on patient outcomes. Conditioning regimens combining busulfan (Bu) and fludarabine (Flu) with or without clofarabine (Clo) are gaining interest worldwide in HCT. To evaluate and possibly adjust full conditioning exposure a simultaneous analysis of Bu, F-ARA-A (active metabolite of Flu) and Clo in one analytical run would be of great interest. However, this is a chromatographical challenge due to the large structural differences of Bu compared to F-ARA-A and Clo. Furthermore, for the bioanalysis of drugs it is common to use stable isotope labelled standards (SILS). However, when SILS are unavailable (in case of Clo and F-ARA-A) or very expensive, standard addition may serve as an alternative to correct for recovery and matrix effects. This study describes a fast analytical method for the simultaneous analysing of Bu, Clo and F-ARA-A with liquid chromatography-tandem mass spectrometry (LC-MS/MS) including standard addition methodology using 604 spiked samples. First, the analytical method was validated in accordance with European Medicines Agency guidelines. The lower limits of quantification (LLOQ) were for Bu 10μg/L and for Clo and F-ARA-A 1μg/L, respectively. Variation coefficients of LLOQ were within 20% and for low medium and high controls were all within 15%. Comparison of Bu, Clo and F-ARA-A standard addition results correspond with those obtained with calibration standards in calf serum. In addition for Bu, results obtained by this study were compared with historical data analysed within TDM. In conclusion, an efficient method for the simultaneous quantification of Bu, Clo and F-ARA-A in plasma was developed. In addition, a robust and cost-effective method to correct for matrix interference by standard addition was established.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Busulfan; Clofarabine; Fludarabine; LC–MS/MS; Standard addition

Mesh:

Substances:

Year:  2017        PMID: 28445850     DOI: 10.1016/j.jchromb.2017.04.025

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle.

Authors:  Mohsin El Amrani; Camiel Göbel; Annelies C Egas; Stefan Nierkens; C Erik Hack; Alwin D R Huitema; Erik M van Maarseveen
Journal:  J Transl Autoimmun       Date:  2019-05-28

2.  Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Authors:  Jurgen B Langenhorst; Thomas P C Dorlo; Erik M van Maarseveen; Stefan Nierkens; Jürgen Kuball; Jaap Jan Boelens; Charlotte van Kesteren; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

3.  Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.

Authors:  Linde Dekker; Friso G Calkoen; Yilin Jiang; Hilly Blok; Saskia R Veldkamp; Coco De Koning; Maike Spoon; Rick Admiraal; Peter Hoogerbrugge; Britta Vormoor; H Josef Vormoor; Henk Visscher; Marc Bierings; Marieke Van Der Vlugt; Harm Van Tinteren; A Laura Nijstad; Alwin D R Huitema; Kim C M Van Der Elst; Rob Pieters; Caroline A Lindemans; Stefan Nierkens
Journal:  Blood Adv       Date:  2022-04-12

4.  A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.

Authors:  Borje S Andersson; Peter F Thall; Junsheng Ma; Benigno C Valdez; Roland Bassett; Julianne Chen; Sairah Ahmed; Amin Alousi; Qaiser Bashir; Stefan Ciurea; Alison Gulbis; Rita Cool; Jitesh Kawedia; Chitra Hosing; Partow Kebriaei; Steve Kornblau; Alan Myers; Betul Oran; Katayoun Rezvani; Nina Shah; Elizabeth Shpall; Simrit Parmar; Uday R Popat; Yago Nieto; Richard E Champlin
Journal:  Bone Marrow Transplant       Date:  2022-05-24       Impact factor: 5.174

5.  Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation.

Authors:  Jurgen B Langenhorst; Thomas P C Dorlo; Charlotte van Kesteren; Erik M van Maarseveen; Stefan Nierkens; Moniek A de Witte; Jaap Jan Boelens; Alwin D R Huitema
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-04-21

6.  Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients.

Authors:  A Laura Nijstad; Stefan Nierkens; Caroline A Lindemans; Jaap Jan Boelens; Marc Bierings; A Birgitta Versluys; Kim C M van der Elst; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2021-02-01       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.